Mesoblast Ltd MESO +7.67% announced the acquisition of a global exclusive license for a patented chimeric antigen receptor (CAR) technology. This platform is aimed at enhancing the effectiveness of therapeutic mesenchymal lineage stromal cell products. By integrating this engineered CAR technology, Mesoblast intends to improve the specificity of its products while amplifying their innate capabilities in immunomodulation and tissue regeneration.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.